Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Foundayo Data Could Broaden Lilly's Obesity Market Opportunity
Participants on the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, Lilly said
Eli Lilly (LLY) shares rose early Monday after the drugmaker said its experimental obesity drug reta
Eli Lilly and Company (NYSE:LLY) shares gained 4. 5% after the pharmaceutical giant unveiled additional clinical data on its obesity treatment retatrutide during the American Diabetes Association (ADA) conference over the weekend.
Eli Lilly reported promising data for Retatrutide and Foundayo at the American Diabetes Association (ADA) 86th Scientific Sessions over the weekend.
Eli Lilly (NYSE:LLY) reported Phase 3 results for obesity drugs retatrutide and Foundayo at the American Diabetes Association 86th Scientific Sessions in 2026. The data show strong weight loss outcomes and benefits in related conditions such as sleep apnea, knee osteoarthritis pain, and type 2 diabetes. The trials include at-risk groups, including women at different life stages and patients with multiple metabolic conditions. Eli Lilly is already widely followed for its work in diabetes and...
The weight-loss rivals provided positive updates on their obesity treatments but to differing reactions among investors.
A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.
Retail sentiment remained constructive. Stocktwits data showed traders continued to maintain a ‘bullish’ stance on SPY and ‘neutral’ on QQQ.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting with Eli Lilly (NYSE:LLY).
Solidion Technology, Eli Lilly, and Citigroup clocked fresh yearly highs amid breakthrough technology announcements, clinical data expectations, and broader market optimism.
Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster ...
Novo Nordisk could maintain this latest early-mover advantage longer than you think.
More employers are requiring weigh-ins, app tracking and health coaching before approving GLP-1s for losing weight—or dropping coverage altogether.
Eli Lilly (NYSE:LLY) has agreed to acquire three vaccine and infectious disease companies, Curevo, LimmaTech Biologics, and Vaccine Company, in deals totaling nearly US$4b. The acquisitions expand Eli Lilly's reach beyond its core obesity and diabetes franchises into vaccines and infectious diseases. Alongside these acquisitions, Eli Lilly has recently entered partnerships in genetic and RNA based therapies with groups including Ascidian Therapeutics, Hanmi Pharm, and Haisco Pharmaceutical...
Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June 3, 2026. The pullback lands ...
Micron has had a turnaround for the ages, going from a free cash flow negative company to a $1 trillion valuation in a little over a year.
Investing.com -- Eli Lilly and Company announced additional positive results today from pivotal Phase 3 trials of its investigational weight loss drug, retatrutide. The data, presented at the American Diabetes Association Scientific Sessions, positions the triple hormone receptor agonist as a potential next-generation successor to current dual-agonist therapies like tirzepatide. In the 80-week TRIUMPH-1 trial evaluating adults with obesity, participants taking a 12 mg dose of retatrutide lost an
Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious diseases.
For investors wondering if Eli Lilly's share price still makes sense after such strong gains, or if expectations have run ahead of reality, this article focuses squarely on what you are paying versus what you may be getting. The stock last closed at US$1,131.42, with returns of 2.4% over 7 days, 14.6% over 30 days, 4.7% year to date and 48.0% over the past year, alongside a very large 3-year return and around 5x over 5 years. Recent market attention on Eli Lilly has largely centered on its...
Sen. Elizabeth Warren (D-Mass.) criticized President Donald Trump’s trading activity, arguing that the volume and timing of transactions in his investment portfolio raised questions about potential conflicts of interest and reinforced the need to ban government officials from trading on...
Eli Lilly and Company (NYSE:LLY) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending might cause near-term headwind for stocks. Cramer noted that the company’s GLP-1 franchise is the best, as he said: CEO David Ricks is a terrific steward of his shareholders’ capital. Still, at […]
International growth could help push Lilly even higher.
Investing.com -- Pfizer Inc (NYSE:PFE) has unveiled detailed strategy plans and clinical data for its experimental weight-loss injection, aiming to secure a foothold in a competitive market currently dominated by rivals. The New York-based pharmaceutical giant is working to catch up to industry leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), which have captured significant market share through their first-mover advantages. Following earlier clinical setbacks, Pfizer rev
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.
